Unknown OBSERVATIONAL NCT03264859

NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction

Neutrophil Gelatinase-associated Lipocalin (NGAL) and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction

Sponsor: Sheba Medical Center

Conditions No-Reflow Phenomenon STEMI - ST Elevation Myocardial Infarction

Interventions NGAL levels early and post STEMI

Updated 7 times since 2017 Last updated: Aug 28, 2017 Started: Sep 15, 2017 Primary completion: Oct 31, 2018 Completion: Oct 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on No-Reflow Phenomenon and STEMI - ST Elevation Myocardial Infarction, this trial is ongoing. The trial is conducted by Sheba Medical Center and has accumulated 7 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Sep 2019 — Jan 2021 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Sep 2019 [monthly]

Not Yet Recruiting

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting

Phase: NA → None
Sep 2017 — Apr 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sheba Medical Center
Zotal Inc.

Data source: Sheba Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ramat Gan, Israel